Advances in CAR-T Cell Therapy for Treating Acute Myeloid Leukemia:  Challenges and Future Perspectives

Vishnu  MG; Rahul; Jocelin Harriate; Sruthi

doi:10.58222/jkm.v3i2.1199

Authors

Vishnu MG Department of Medical laboratory technology, Acharya institute of allied health sciences
Rahul Department of Medical laboratory technology, Acharya institute of allied health sciences
Jocelin Harriate Department of Medical laboratory technology, Acharya institute of allied health sciences
Sruthi Department of Medical laboratory technology, Acharya institute of allied health sciences

DOI:

https://doi.org/10.58222/jkm.v3i2.1199

Keywords:

CAR-T Cell therapy, Acute Myeloid Leukemia, Chimeric Antigen Receptor

Abstract

This review focuses on the revolutionary capacity of CAR-T therapy in the context of acute myeloid leukemia (AML). It is an area beset with challenges despite its progress in the treatment of hematologic malignancies. Specifically, it narrows down to identifying ideal target antigens such as CD33, CD123, and FLT3 which are pertinent to the challenge of antigen heterogeneity in AML as well as minimizing on-target off-tumor toxicity. These problems are attempted to be eliminated through innovative concepts like the use of dual-targeting CARs, armoured CAR-T cells, and CRISPR-mediated genetic editing techniques, each having a superior safety and efficacy profile.Dual-target CARs have the advantages of improved selectivity; armoured CAR-T cells can survive in the AML immunosuppressive microenvironment, and CRISPR-mediated CAR-T cells ensure precision with minimal side effects. The clinical outcomes in the last few years and a string of recent preclinical studies show promising, albeit challenging, therapeutic results. In any case, such observations mark significant progress toward ensuring long-term remission while tolerable toxicity levels. This chapter draws upon recent clinical trials and research findings in order to put into sharp relief CAR-T therapy's emergent role as a new, life-saving approach for the treatment of AML. Its understanding of technological advancement in CAR-T therapy places this chapter as an invaluable reference source for researchers and clinicians interested in optimizing CAR-T therapy in the treatment of AML

References

Ayala Ceja, M., Khericha, M., Harris, C. M., Puig-Saus, C., & Chen, Y. Y. (2024). CAR-T cell manufacturing: major process parameters and next-generation strategies. Journal of Experimental Medicine, 221(2), e20230903.

Damiani, D., & Tiribelli, M. (2024). CAR-T Cells in Acute Myeloid Leukemia: Where Do We Stand?. Biomedicines, 12(6), 1194.

Dimitri, A., Herbst, F., & Fraietta, J. A. (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Molecular cancer, 21(1), 78.

Ercilla-Rodríguez, P., Sánchez-Díez, M., Alegría-Aravena, N., Quiroz-Troncoso, J., Gavira-O'Neill, C. E., González-Martos, R., & Ramírez-Castillejo, C. (2024). CAR-T lymphocyte-based cell therapies; mechanistic substantiation, applications and biosafety enhancement with suicide genes: new opportunities to melt side effects. Frontiers in Immunology, 15, 1333150.

Greiner, J., Götz, M., & Wais, V. (2022). Increasing Role of Targeted Immunotherapies in the Treatment of AML. International journal of molecular sciences, 23(6), 3304. https://doi.org/10.3390/ijms23063304

Han, H. J., Choi, K., & Suh, H. S. (2024). Impact of aging on acute myeloid leukemia epidemiology and survival outcomes: A real-world, population-based longitudinal cohort study. Plos one, 19(5), e0300637.

Khaniya, A., Rad, S. M. A. H., Halpin, J., Tawinwung, S., McLellan, A., Suppipat, K., & Hirankarn, N. (2024). Development of a compact bidirectional promoter-driven dual chimeric antigen receptor (CAR) construct targeting CD19 and CD20 in the Sleeping Beauty (SB) transposon system. Journal for immunotherapy of cancer, 12(4), e008555. https://doi.org/10.1136/jitc-2023-008555

Koedam, J., Wermke, M., Ehninger, A., Cartellieri, M., & Ehninger, G. (2022). Chimeric antigen receptor T-cell therapy in acute myeloid leukemia. Current opinion in hematology, 29(2), 74–83. https://doi.org/10.1097/MOH.0000000000000703

Loff, S., Dietrich, J., Meyer, J. E., Riewaldt, J., Spehr, J., von Bonin, M., Gründer, C., Swayampakula, M., Franke, K., Feldmann, A., Bachmann, M., Ehninger, G., Ehninger, A., & Cartellieri, M. (2020). Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia. Molecular therapy oncolytics, 17, 408–420. https://doi.org/10.1016/j.omto.2020.04.009

Ma, J., & Ge, Z. (2021). Recent advances of targeted therapy in relapsed/refractory acute myeloid leukemia. Bosnian journal of basic medical sciences, 21(4), 409–421. https://doi.org/10.17305/bjbms.2020.5485

Mardiana, S., & Gill, S. (2020). CAR T cells for acute myeloid leukemia: state of the art and future directions. Frontiers in oncology, 10, 697.

Mohty, R., & Lazaryan, A. (2024). "Off-The-Shelf" allogeneic chimeric antigen receptor T-cell therapy for B-cell malignancies: current clinical evidence and challenges. Frontiers in oncology, 14, 1433432. https://doi.org/10.3389/fonc.2024.1433432

Pérez-Amill, L., Bataller, À., Delgado, J., Esteve, J., Juan, M., & Klein-González, N. (2023). Advancing CART therapy for acute myeloid leukemia: recent breakthroughs and strategies for future development. Frontiers in Immunology, 14, 1260470

Tomasik, J., Jasiński, M., & Basak, G. W. (2022). Next generations of CAR-T cells-new therapeutic opportunities in hematology?. Frontiers in Immunology, 13, 1034707.

Vanhooren, J., Dobbelaere, R., Derpoorter, C., Deneweth, L., Van Camp, L., Uyttebroeck, A., ... & Lammens, T. (2023). CAR-T in the treatment of acute myeloid leukemia: barriers and how to overcome them. Hemasphere, 7(9), e937.

Wei, W., Chen, Z. N., & Wang, K. (2023). CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. International journal of molecular sciences, 24(15), 12317. https://doi.org/10.3390/ijms241512317

Xiao, K., Lai, Y., Yuan, W., Li, S., Liu, X., Xiao, Z., & Xiao, H. (2024). mRNA‐based chimeric antigen receptor T cell therapy: Basic principles, recent advances and future directions. Interdisciplinary Medicine, 2(1), e20230036.

Zarychta, J., Kowalczyk, A., Krawczyk, M., Lejman, M., & Zawitkowska, J. (2023). CAR-T Cells Immunotherapies for the Treatment of Acute Myeloid Leukemia-Recent Advances. Cancers, 15(11), 2944. https://doi.org/10.3390/cancers15112944